Pfizer Seen Beating Market Through 2031 on 20 Pivotal Studies and New Drug Growth
Updated
Updated · The Motley Fool · May 12
Pfizer Seen Beating Market Through 2031 on 20 Pivotal Studies and New Drug Growth
2 articles · Updated · The Motley Fool · May 12
Pfizer is projected to outperform through 2031 even after its stock fell 35% over five years, with the bullish case centered on newer medicines and a deeper late-stage pipeline.
Q1 revenue rose 5% to $14.5 billion as newer products gained traction: Abrysvo sales climbed 37% to $180 million, Elrexfio 34% to $80 million, and Padcev 39% to $591 million.
That growth matters because older blockbusters are fading—among Eliquis, Ibrance, Comirnaty and Paxlovid, only Eliquis grew in 2025, and it also faces patent expiry within the next few years.
Pfizer is also lining up about 20 pivotal studies in 2026, including obesity candidates such as monthly MET-097i and licensed GLP-1 drug ecnoglutide, which showed 15.1% average weight loss over 48 weeks.
With the stock trading at 8.8 times forward earnings versus 16.8 for healthcare peers, the view is that patent-cliff risks are largely priced in and pipeline progress could rerate the shares.
Can Pfizer's new drugs outpace its looming multi-billion dollar patent cliff, or is the stock a classic value trap for investors?
Has Pfizer's multi-billion dollar acquisition spree secured its future growth or just created a more complex and riskier company?
As a latecomer to the weight-loss drug race, can Pfizer’s monthly shot truly challenge the established market leaders?